This technology holds several competitive advantages in the field of Ebola virus disease (EVD) treatment. Firstly, it addresses a critical gap in the current EVD therapeutic landscape by targeting host cell signaling pathways, offering a novel approach distinct from conventional antiviral strategies. Secondly, the technology has demonstrated efficacy in reducing EVD progression in both cell culture and animal models, providing strong preclinical evidence of its potential effectiveness. Additionally, the identification of specific kinase inhibitors as therapeutic candidates highlights the precision and specificity of this approach, minimizing off-target effects and enhancing safety profiles. Lastly, by elucidating the role of key signaling pathways in EVD pathogenesis, this technology not only offers therapeutic potential but also provides valuable insights into the molecular mechanisms underlying viral hemorrhagic fevers, paving the way for future advancements in the field.